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Extensive studies of human T-cell leukemia virus (HTLV)-1 and HTLV-2 over the last three
decades have provided detailed knowledge on viral transformation, host–viral interactions
and pathogenesis. HTLV-1 is the etiological agent of adult T cell leukemia and multiple
neurodegenerative and inﬂammatory diseases while HTLV-2 disease association remains
elusive, with few infected individuals displaying neurodegenerative diseases similar to
HTLV-1. The HTLV group of oncoretroviruses has a genome that encodes structural and
enzymatic proteins Gag, Pro, and Env, regulatory proteins Tax and Rex, and several
accessory proteins from the pX region. Of these proteins, HTLV-1 p30 and HTLV-2 p28
are encoded by the open reading frame II of the pX region. Like most other accessory
proteins, p30 and p28 are dispensable for in vitro viral replication and transformation but
are required for efﬁcient viral replication and persistence in vivo. Both p30 and p28 regulate
viral gene expression at the post-transcriptional level whereas p30 can also function at
the transcriptional level. Recently, several reports have implicated p30 and p28 in multiple
cellular processes, which provide novel insight into HTLV spread and survival and ultimately
pathogenesis. In this review we summarize and compare what is known about p30 and
p28, highlighting their roles in viral replication and viral pathogenesis.
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INTRODUCTION
Human T-cell leukemia virus (HTLV) are complex deltaretro-
viruses, with HTLV-1 and HTLV-2 causing the most prevalent
worldwide infections. HTLV-1 infects approximately 25 million
people worldwide and is endemic in Japan, Africa, South Amer-
ica, Iran, and the Caribbean basin (Proietti et al., 2005; Goncalves
et al., 2010; Iwanaga et al., 2012). In contrast, HTLV-2 is endemic
in Central and West Africa (Goubau et al., 1992; Gessain et al.,
1993; Goubau et al., 1993), in native Amerindian populations in
North, Central, and South America (Hjelle et al., 1990; Lairmore
et al., 1990; Heneine et al., 1991; Levine et al., 1993), and among
cohorts of intravenous drug users (IVDUs) in the United States
and Europe. Although few HTLV-1 infected individuals (1–5%)
develop adult T-cell leukemia/lymphoma (ATL/ATLL) or HTLV-
1-associated myelopathy/tropic spastic paraparesis (HAM/TSP),
all infected individuals exhibit a persistent antiviral immune
response that fails to clear the virus (Poiesz et al., 1980; Yoshida
et al., 1982; Takatsuki, 2005; Yoshida, 2005; Lairmore et al.,
2012). Furthermore, HTLV-2 infection is not associated with
leukemia/lymphoma, although in rare cases it causes a neu-
rodegenerative condition similar to HAM/TSP (Araujo and Hall,
2004).
The genome of HTLV encodes structural and enzymatic genes
typical of all retroviruses. In addition, the pX region located
between the env gene and 3′ long terminal repeat (LTR) encodes
four open reading frames (ORF I to IV) with a potential for
encoding several proteins (Berneman et al., 1992; Ciminale et al.,
1992; Koralnik et al., 1992). As a result of complex splicing, various
mRNAs encode regulatory and accessory proteins. Positive regula-
tors of viral gene expression, Tax and Rex, are encoded by a doubly
spliced bicistronic mRNA fromORFs IV and III, respectively (Fel-
ber et al., 1985; Kiyokawa et al., 1985). Reverse transcription-PCR
of mRNA fromHTLV-1 infected cell lines and uncultured primary
lymphocytes from ATL patients has shown that alternative splic-
ing produces the accessory proteins p12, p30, and p13 (Berneman
et al., 1992; Ciminale et al., 1992; Koralnik et al., 1992). A singly
spliced mRNA containing ORF-I codes for the accessory protein
p12 that can be cleaved to produce a smaller protein, p8 (Van
Prooyen et al., 2010). p30 is encoded by a doubly spliced message
in which ORF-II is linked to the Tax initiation codon located on
exon II, resulting in a 241 amino acid protein. ORF-II also can
be singly spliced to produce mRNA that can encode p13 from the
internal initiation codon in ORF-II, which corresponds essentially
to the last 87 amino acids of p30. Similar studies in the MoT cell
line identiﬁed accessory proteins in HTLV-2: a bicistronic dou-
bly spliced mRNA encodes p10 and p11 from ORF-I and ORF-V,
respectively, and two distinct bicistronic singly spliced mRNAs
encoded p28 fromORF II as well as the truncatedORF III isoforms
of Rex (Ciminale et al., 1995). p30 and p28 share certain amino
acid sequence homology, the last 50 amino acids of p30 share
70% homology with the ﬁrst 50 amino acids of p28 (Ciminale
et al., 1995), and both are nuclear/nucleolar proteins (Koralnik
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et al., 1993; Ciminale et al., 1995; D’Agostino et al., 1997; Younis
et al., 2004). In addition, newly identiﬁed proteins, HTLV-1 basic
leucine zipper factor (HBZ) and anti-sense proteinHTLV-2 (APH-
2), are encoded from the antisense genome strand in HTLV-1 and
HTLV-2, respectively (Gaudray et al., 2002; Halin et al., 2009).
Tax transactivates viral gene transcription by recruiting tran-
scription factors p300/CREB binding protein (CBP), CREB and
AP-1 to the Tax response element (TRE) in the LTR region (Seiki
et al., 1986). Tax drives cellular transformation through its abil-
ity to alter cellular gene expression, signaling pathways, and cell
cycle (Grassmann et al., 2005). Of the factors targeted by Tax,
NFκB clearly plays a prominent role in deregulation of cellular
gene expression and cellular transformation (Smith and Greene,
1990; Rosin et al., 1998; Robek and Ratner, 1999; Ross et al.,
2000). Although Tax is indispensable for viral transformation, the
mechanism by which the virus persists in vivo leading to T-cell
transformation is not clearly understood (Matsuoka and Jeang,
2007). Studies suggest that HBZ and accessory proteinsmight play
a role in vivo in HTLV-1 viral persistence and T-cell malignant
transformation (Bartoe et al., 2000; Arnold et al., 2006; Arnold
et al., 2008; Valeri et al., 2010). Rex binds to the Rex response
element (RxRE) on unspliced and singly spliced viral mRNAs to
facilitate their nuclear-cytoplasmic export for translation in the
cytoplasm (Younis and Green, 2005). p30 and p28 mRNA species
can be identiﬁed in infected cells (Li and Green, 2007) and in cells
from HTLV-1 infected patients (Rende et al., 2011; Bender et al.,
2012), albeit at 103–104 lower levels than tax/rex mRNA.
Reports identifying antibodies and cytotoxic CD8+ T-cells in
infected patients with HTLV-1 (symptomatic and asymptomatic)
against p30, demonstrate the importance of HTLV-1 accessory
proteins in viral persistence and ultimately in the viral life cycle
(Jacobson et al., 1992; Chen et al., 1997; Pique et al., 2000). How-
ever no studies to date have attempted to identify antibodies or
cytotoxic CD8+ T-cells against p28 in HTLV-2 infected patients.
In this review we will compare the current knowledge on p30 and
p28, highlighting the differences and similarities in their roles in
the HTLV life cycle.
IN VIVO ROLE OF P30 AND P28
Initial studies to understand the role of p30 were performed by
deleting either ORF-I and –II, or ORF II alone from an HTLV-1
infectious molecular clone, which showed that p30 is dispens-
able for viral gene expression, infectivity, replication, and T-cell
immortalization in vitro (Derse et al., 1997; Robek et al., 1998). To
examine the role of p30 in viral replication and infectivity in vivo,
T-cell lines immortalized with a viral clone containing mutations
ablating both p30 and p13 reading frames (Bartoe et al., 2000) or
p30 alone (Silverman et al., 2004) were generated. It was noted
that loss of p30 and p13 or p30 alone resulted in a signiﬁcantly
reduced antibody response and lower proviral loads in rabbits
indicating that p30 and p13 are required for maintenance of high
proviral loads in vivo (Bartoe et al., 2000; Silverman et al., 2004).
In addition, when p30 alone was ablated, reversion to the wild type
sequence was observed, underlining the in vivo importance of p30
in maintaining high level viral infection (Silverman et al., 2004). It
is noteworthy that these ﬁrst experiments were performed before
the identiﬁcation of the HTLV-1 HBZ, which is encoded from
the anti-sense viral mRNA that overlaps ORFs in the pX region
including p30 ORF-II (Gaudray et al., 2002). It is very likely that
the mutations ablating p30 expression interfered with the expres-
sion of HBZ, which also was shown to be important for viral
infectivity in vivo (Arnold et al., 2006). Recently, to investigate the
relative contribution of HBZ and p30 to viral infectivity in vivo,
B cell lines expressing viral mutants with speciﬁc ablation of HBZ
and p30 were generated and used to infect rabbits and macaques.
In contrast to the earlier in vivo rabbit studies (Silverman et al.,
2004), it was shown that viral mutants lacking p30 had little effect
on antibody response, infectivity or proviral loads. However, lack
of HBZ resulted in reduced proviral loads in rabbits. In addition,
there was no evidence of reversion to wild type sequence by the
p30 or HBZmutants (Valeri et al., 2010). Interestingly, inmacaque
infections it was noted that lack of p30 and HBZ resulted not only
in reduced antibody response and infectivity but also reversion to
wild type sequence indicating that p30 andHBZ are important for
viral infectivity in macaques (Valeri et al., 2010). The discrepancy
regarding the requirement for p30 in rabbit infections may be due
to the contribution of HBZ to the viral infection. In the same
study it was shown that p30 is also required for productive cell-
free infection of dendritic cells in vitro. The requirement of p30 in
terms of in vitro viral infection might be cell type-dependent.
On the other hand, an initial report revealed that deletion of the
pX region of HTLV-2 causes a reduction in viral replication but not
infectivity in vivo, but had no effect in vitro (Cockerell et al., 1996).
To delineate the role of p28, Yamamoto et al. (2008) created a p28
knockout HTLV-2 molecular clone and stably transfected virus
producing cells with the wild type HTLV-2 molecular clone or
the HTLV-2p28 mutant. The irradiated producer cells were co-
cultured with human PBMCs, and viral p19 Gag production and
cell survival were measured over time. No difference was observed
between HTLV-2 and HTLV-2p28 indicating that p28 was not
required for in vitro primary T lymphocyte infectivity, prolifera-
tion, and immortalization. The authors also determined the effect
of p28 on viral persistence in vivo using a rabbit model and found
that rabbits infected with HTLV-2 lacking p28 had lower antibody
responses and reduced proviral load compared to those infected
with wild type HTLV-2 (Yamamoto et al., 2008). The mutation
to delete p28 had no effect on the APH-2 gene providing clear
evidence that p28 contributes to viral persistence in vivo.
Collectively, it is clear that p30 (HTLV-1) and p28 (HTLV-2)
are required for efﬁcient viral replication and persistence in vivo.
Recent ﬁndings discussed below provide various possible mech-
anisms to explain the role of these accessory proteins in viral
infection and/or pathogenesis.
VIRAL GENE EXPRESSION
TRANSCRIPTIONAL REGULATION
It was demonstrated that p30 is a nuclear/nucleolar localizing pro-
tein (Ciminale et al., 1992; Koralnik et al., 1992; see Figure 1 for
summary of key p30 domains). Structurally, p30 contains a bipar-
tite nucleolar/nuclear localization signal (NoRS/NLS), which is
comprised of two arginine rich domains (amino acids 73–78 and
91–98; D’Agostino et al., 1997). A later study reconﬁrmed these
regions to be a nucleolar retention signal and also identiﬁed two
other possible nuclear localization signals in the amino (N) and
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FIGURE 1 | Schematic representation of the known/putative functional
domains of p30. (*)K106 required for p30TRE transcriptional repression.
(#)T232 required for nucleolus to nuclear transport upon DNA damage.
NLS, nuclear localization sequence; NoRS, nucleolar retention sequence;
Rex-BD, Rex binding domain; TIP60-BD, TIP60 binding domain; aa, amino
acids.
carboxy (C) termini of p30 (Ghorbel et al., 2006). The latter study
also implicated the role of transcription and RNA-interaction in
nucleolar/nuclear localization of p30 with the speciﬁc interac-
tion of p30 with a 60S ribosomal protein L18a (Ghorbel et al.,
2006). Similar to p30, expression of p28 cDNA resulted in nuclear
localization of p28 (Ciminale et al., 1995; Younis et al., 2004).
p30 has marked homology with serine and threonine rich tran-
scription factors Oct-1 and-2, Pit-1, and POU-M1 suggesting that
p30 could function as a transcriptional regulator (Ciminale et al.,
1992). The initial evidence of p30 as a transcriptional regulator
was provided by the ability of p30 to differentially modulate CREB
responsive promoters by acting as a transactivator when fused to
the DNA binding domain of Gal4, and behaving as a repressor
when expressed alone. In addition, p30 increased transcription
from the TRE at a low concentration but repressed transcription at
a higher concentration in the presence and absence of Tax (Zhang
et al., 2000). On the other hand, in a similar Gal4 reporter assay,
p28 failed to modulate Gal4 DNA binding ability, demonstrating
that p28 is devoid of transcriptional activity (Younis et al., 2006).
Subsequently, p30 was shown to regulate transcription by binding
to CBP/p300. The interaction of p30 and CBP/p300 was evaluated
by two hybrid screening, immunoprecipitation, and localization
studies. The binding of p30 to p300 was mapped to a highly con-
served KIX region of p300, which is also the binding site of Tax.
The transcriptional repression of TRE by p30 is a result of compe-
tition between p30 and Tax for p300 binding and disruption of the
assembly of Tax/CBP/P300 on the TRE (Zhang et al., 2001). The
p300 binding region was mapped to amino acids 1–132 whereas
the TRE transcription repression function of p30 was mapped
to amino acids 100–179. This 80 bp region contains ﬁve of the
six lysine residues in p30 of which lysine 106 was found to be
important for repression. Unlike wild type p300, mutant p300
with impaired histone acetyltransferase activity (HAT) was unable
to rescue p30-mediated LTR transcription repression. Moreover,
p30 LTR repression was enhanced by histone deacetylase (HDAC-
1) and inhibited by Trichostatin A (inhibitor of HDAC-1). These
data suggest that the LTR transcription repression function of p30
could be regulated by acetylation on lysine or that these effects
are due to global effects of HATs and HDACs on transcription
(Michael et al., 2006).
p30 has the ability to transcriptionally activate numerous cel-
lular genes. In one study it was shown that p30 binds and stabilizes
the Myc/Tat-interacting protein (TIP60) transcriptional com-
plex (Awasthi et al., 2005). Furthermore, p30 binds and recruits
the 60-kDa (TIP60) to the Myc transcription complex to acti-
vate Myc responsive genes, which requires the HAT of TIP60.
In addition, the transcriptional activity of p30 was dependent
on transforming transcriptional activator protein (TRRAP)/p434.
The idea that p30 plays a role in transformation by enhancing
Myc-responsive genes was supported by the data showing that
p30 cooperated with Myc in focus-forming transformation assays
(Awasthi et al., 2005). More evidence for regulation of cellular
transcription by p30 comes from a study showing that p30 can
interact with the PU.1 transcription factor through its DNA bind-
ing domain resulting in the suppression of PU.1 DNA binding.
Subsequently, the expression of p30 decreased cell surface expres-
sion of TLR4 as the expression of TLR4 is directly under the
inﬂuence of PU.1 transcription activation. Concurrently, reduced
TLR4 expression by p30 resulted in reduced pro-inﬂammatory
cytokines TNF-α, MCP-1 and IL-8 whereas the expression of
anti-inﬂammatory cytokine IL-10 was increased. Additionally
it was found that p30 increased phosphorylation of GSK3-β
leading to an increase in IL-10 production (Datta et al., 2006).
These data indicate that p30 can inﬂuence innate and adaptive
immunity to potentially facilitate viral spread by inﬂuencing cel-
lular transcription. Similar experiments to investigate the ability
of p28 to regulate transcription of cellular genes demonstrated
that unlike p30, p28 has no transcription function, although
chromatin immunoprecipitation assays (ChIP) show that p28 is
recruited to the LTR along with the transcriptional machinery
(Younis et al., 2006).
In order to further characterize the role of p30 in cellular tran-
scription, various groups have performedmicroarray analysis. The
initial microarray analysis showed that p30 altered expression of
cellular genes involved in apoptosis, cell cycle regulation, cell adhe-
sion, transcription, and T-cell signaling and activation. It was
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found that p30 selectively activates genes involved in T cell signal-
ing/activation and also enhances transcriptionmediated by NFAT,
NF-κB, andAP-1 when stimulated (Michael et al., 2004). The abil-
ity of p30 to transcriptionally activate numerous cellular genes
was also reported, where p30 binds and stabilizes the Myc/TIP60
transcriptional complex (Awasthi et al., 2005). Recently, similar
microarray analysis also showed that p30 was capable of altering
transcription of cellular genes involved in apoptosis and transcrip-
tion (Taylor et al., 2009). Overall, these data indicate that p30
regulates transcription of viral genes as well as cellular genes to
create an environment that promotes viral gene expression and
survival of infected cells.
POST-TRANSCRIPTIONAL REGULATION
HTLV-1 p30 controls viral gene expression at the post-
transcriptional level by interacting with and retaining tax/rex
mRNA in the nucleus. The expression of p30 results in decreased
levels of tax/rex mRNA speciﬁcally: this effect was not observed
with other viral mRNAs. p30 binds to the second splice junction of
tax/rex mRNA,which then is retained in the nucleus to repress tax
expression and, in turn, viral gene expression (Nicot et al., 2004).
HTLV-2 p28mediates nuclear retention of the tax/rexmRNA via a
similar post-transcriptional mechanism (Younis et al., 2004). You-
nis et al. (2006) went on to demonstrate that both p28 and p30 are
recruited by Tax to the viral promoter, which then bind to their
respective de novo transcribed response elements leading to the
retention of tax/rex mRNA in the nucleus.
Rex and p30 have antagonistic functions where the Rex protein
facilitates the nuclear-cytoplasmic export of unspliced and singly
splicedmRNAwhile p30 retains tax/rex mRNA in the nucleus. The
Rex and p30 interaction is favored when p30 is bound to tax/rex
mRNA. The interaction of p30 with Rex has no effect on the abil-
ity of Rex to export mRNA from the nucleus to the cytoplasm
whereas Rex moderately rescues the nuclear retention of tax/rex
mRNA in the nucleus by p30. This interplay between p30 and Rex
may be critical to establishing HTLV-1 latency (Sinha-Datta et al.,
2007). Immunoﬂuorescence confocalmicroscopy showed that p30
and Rex localized with CRM1, suggesting an interaction between
Rex and p30 in HTLV-1 post-transcriptional control (Baydoun
et al., 2007). On the other hand, p28 inhibited tax/rex mRNA
export through theTAP/p15pathway andnotCRM1,where exoge-
nous expression of TAP/p15 rescued p28 post-transcriptional
repression (Younis et al., 2006).
Recently, microarray studies demonstrated that p30 can reg-
ulate cellular gene expression at the post-transcriptional level as
well. Cytoplasmic expression of genes involved in cell signaling,
transcription, translation, replication, cytoskeleton, DNA, and
metabolism was decreased while those involved in repair, apopto-
sis, cell adhesion, and signaling were increased (Taylor et al., 2009).
Studies to evaluate the effect of p28 post-transcriptional regula-
tion on cellular genes have not been performed and are worth
investigating.
CELL CYCLE REGULATION
Cell cycle control is an intricate, highly regulated pathway that
guarantees proper cellular turnover and involves various cyclin
dependent kinases (CDK) and Cyclins that phosphorylate key
molecules allowing cell cycle progression. Different studies have
shown that p30 also inﬂuences cell cycle progression. The G2/M
checkpoint is regulated by a tight balance of phosphorylation
and dephosphorylation events, where Cdc25c plays a crucial role
in the onset of mitosis (Draetta and Eckstein, 1997). p30 acti-
vates the G2/M checkpoint by increasing the phosphorylation of
Chk1 and subsequently increasing phosphorylation of Cdc25c.
Another mechanism of p30-induced G2/M cell cycle arrest would
be via reduction of PLK1 levels and phosphorylation result-
ing in decreased phosphorylation of Cdc25. In support of this
mechanism, cells immortalized with an HTLV-1 molecular clone
lacking p30 were more susceptible to apoptosis when treated with
camptothecin and etoposide (Datta et al., 2007).
In addition to the effects of p30 on the G2M checkpoint, p30
activates Myc-driven genes leading to increased S phase progres-
sion and polyploidy (Awasthi et al., 2005). However, a recent study
reported that expression of p30 delays S phase entry (Baydoun
et al., 2010). The CDK2–Cyclin E complex is known to phospho-
rylate Rb, which in turn releases the transcriptional factor E2F,
thereby controlling the expression of several genes required for
S phase entry. It was shown that p30 delays S phase entry by
interacting with both Cyclin E and CDK2 affecting their complex
formation and resulting in reduced phosphorylation of Rb (Ver-
meulen et al., 2003). Hence, p30 expression causes a decrease in
E2F and Cyclin E levels, and an increase in p21Waf expression. In
contrast to p30, the expression of p28 had no effect on S phase
entry and p28 was incapable of binding to Cyclin E (Baydoun
et al., 2010).
DNA DAMAGE AND REPAIR
The integrity of the genome is essential for cell propagation, and
timely repair of DNA damage is equally important to avoid the
accumulation of mutations that could result in tumorigenesis.
Retrovirus integration elicits the double stranded DNA dam-
age response where cells must repair DNA damage in order to
avoid apoptosis. DNA double strand breaks (DSB) are highly
toxic to cells and are associated with developmental, immuno-
logical, neurological disorders, and various cancers (Jackson and
Bartek, 2009; McKinnon, 2009). Anupam et al. (2011) demon-
strated that p30 confers a growth advantage to cells that have
undergone double-stranded DNA damage. It was shown that p30
interacts with ATM and reduces the levels of ataxia telangiectasia
mutated (ATM) and phosphorylated ATM upon double stranded
DNA damage. Mass spectrometric studies identiﬁed REGγ, a
nuclear proteasome activator, as a cellular binding factor of p30
that might target ATM for degradation. This mechanism of p30
targeting ATM to the proteasome for degradation through inter-
action with REGγ is consistent with co-elution of ATM, p30,
and REGγ in the same size exclusion chromatography fractions
(Anupam et al., 2011). Lowering the levels of ATM by p30 upon
DNA damage would decrease p53-mediated apoptosis thereby
facilitating survival of infected cells. Interestingly, the levels of
p30 corresponded to the levels of REGγ (Anupam et al., 2011).
Another study showed that p30 translocates from the nucleolus
to the nucleus upon DNA damage via phosphorylation at thre-
onine 232, which is part of a mitogen-activated protein kinase
(MAPK) domain in the carboxy terminus. The expression of p30
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inhibits homologous recombination and favors non-homologous
recombination in natural and induced DNA damage conditions.
p30 inhibits homologous DNA damage by interfering with the
assembly of the MRE11/RAD50/NBS1 (MRN) complex by inter-
acting with RAD50 and NBS1. The amino terminal of p28 has a
similar MAPK domain except for a proline in the place of thre-
onine. Mutating this proline to threonine to mimic the MAPK
domain of p30 did not enable p28 to alter DNA repair (Bay-
doun et al., 2011). The interaction between p30 and REGγ was
conﬁrmed by another study using a similar mass spectrometric
technique (Ko et al., 2013). However, this study showed that the
ability of p30 to retain tax/rexmRNA in the nucleuswas dependent
on recruiting REGγ to the tax/rex mRNA by p30. Further, reduced
levels of REGγ resulted in increased HTLV-1 gene expression (Ko
et al., 2013). In contrast, another study showed that reduced lev-
els of REGγ had no effect on HTLV-1 gene expression (Doueiri
et al., 2012). The discrepancy about the role of p30 and REGγ
binding could be explained by the use of different cell lines and
techniques.
p30 AND p28 INTERACTOMES
The comparative studies of HTLV-1 and HTLV-2 are useful to
highlight the differences that might be responsible for HTLV-1
pathogenesis. Studies investigating host–viral protein interactions
have been centered on Tax-1 and Tax-2. Moreover, a large amount
of work has focused on p30 because HTLV-1 is pathogenic while
similar comparative studies have not been performed on p28. Our
group performed a mass spectrometry-based analysis to com-
pare the p30 and p28 interactomes in terms of host–protein
interactions. The mass spectrometry results suggested that p30
interacts with a larger and wider range of proteinsmainly involved
in cell cycle regulation, cell survival, DNA repair, cancer path-
ways, protein post-translational modiﬁcations, and metabolism,
whereas p28 interacts with a smaller number of proteins that
are involved in mRNA processing and protein post-translational
modiﬁcations. These data are consistent with the known func-
tions of p30 and p28. Furthermore, we conﬁrmed the interaction
between p30 and REGγ and also showed that p28 does not
interact with REGγ. Tagging RNA for export is a complex pro-
cess that involves several proteins involved in splicing such as
the SR protein complex and hnRNPs (Caputi and Zahler, 2002;
Han et al., 2010; Busch and Hertel, 2012). The exact mecha-
nism utilized by p28 and p30 to retain tax/rex mRNA is not
known; however, the mass spectrometry analyses identiﬁed inter-
actions between p28 and hnRNP H1 and hnRNP F. Conversely,
p30 does not have an interaction with hnRNP H1(Doueiri et al.,
2012). However, hnRNP K was identiﬁed to interact with both
p30 and p28. We postulate that p30 and p28 might use these
interactions to modulate the role of hnRNPs or other proteins
involved in RNA export, which could be a possible mechanism
for retention of tax/rex mRNA in the nucleus. However the full
implication of these interactions warrants further investigation.
In addition, a novel interaction between p30 and NEAP interact-
ing protein 30 (NIP30) was also identiﬁed. NIP30 is predicted
to bind DNA binding/EF hand/Leucine zipper protein (NEFA),
which has been shown to localize to the Golgi complex. Prelimi-
nary characterization of NIP30 indicated that it is a nuclear protein
(Simpson et al., 2000). Since the biological function of NIP30 is
not known, further investigation is required to understand the
importance of the interaction between p30 and NIP30 (Doueiri
et al., 2012).
Interestingly, both p30 and p28 interact with protein arginine
methyltransferase 5 (PRMT5). It has been shown that PRMT5 can
regulate transcription and also is involved in mRNA processing,
mainly splicing (Karkhanis et al., 2011). Moreover, PRMT5 is up-
regulated in B cell lymphomas and most transformed cell lines
(Wang et al., 2008). The signiﬁcance of the PRMT5 interaction
was investigated by evaluating the effect of PRMT5 knockdown on
viral gene expression. Intriguingly, lower levels of PRMT5 signiﬁ-
cantly reduced HTLV-2 gene expression, whereas no such effect
was seen on HTLV-1 gene expression. It remains to be deter-
mined whether the p28–PRMT5 interaction regulates HTLV-2
gene expression at the transcriptional or post-transcriptional level.
The interaction between p30 and PRMT5 could be important at a
stage of viral spread and/or pathogenesis other than gene expres-
sion. This study provides a novel hypothesis about the role of p30
and p28 in the different pathological outcomes of HTLV-1 and
HTLV-2 (Doueiri et al., 2012). A summary of various molecular
process in which HTLV-1 p30 and HTLV-2 p28 are involved is
shown in Figure 2.
SUMMARY
Human T-cell leukemia virus (HTLV)-1 and HTLV-2 are related
retroviruses that have different pathological outcomes. While
HTLV-1 infection is linked to cancer, inﬂammatory and neu-
rodegenerative diseases, HTLV-2 is minimally pathogenic. The
differences in the viral oncoprotein Tax-1 and Tax-2 are in part
responsible for the distinct outcomes of infection with these
viruses. However the absence of Tax expression in most ATL
patients and the requirement for the accessory genes in HTLV
persistence in in vivo models demonstrate a more complex viral
regulatory mechanism that allows the virus to infect and persist
in the host. HTLVs encode various proteins that affect multi-
ple signaling nodes (Simonis et al., 2012) thereby ensuring tight
control of the cellular mechanisms required for infectivity, per-
sistence, and spread, while down-regulating those involved in
limiting viral spread. HTLV-1 p30 and its homologue HTLV-2
p28 are accessory proteins required for viral persistence in vivo,
but are dispensable for in vitro viral persistence. p30 and p28
are both post-transcriptional negative regulators of viral repli-
cation; they interact with tax/rex mRNA and retain it in the
nucleus, therebymodulating oncogenic/immunogenic Tax expres-
sion allowing the virus to escape immune surveillance while
slowly transforming the infected cells. In addition, p30 functions
in transcriptional and post-transcriptional mechanisms indepen-
dent of Tax. p30 causes G2/M cell cycle arrest and delays S
phase entry, down-regulates ATM and favors NHEJ, modulates
the innate immune response and increases the expression of genes
involved in T-cell survival and expansion, while down-regulating
genes involved in apoptosis. Interestingly, although the ﬁrst 50
amino acids of p28 share 77% homology with the last 50 amino
acids of p30, this polypeptide domain is devoid of transcrip-
tional activity or effects on the host cell cycle, DNA damage
response or immune response. Proteome analysis revealed that
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FIGURE 2 | (A) Schematic representation of p30 functions. (1) Interaction of
p300 and p30 inﬂuences cellular gene expression (2) p30 inhibits PU.1
transcriptional activity, affecting TLR4 expression and ultimately the innate
immune response. (3) p30 activates Myc-mediated transcription by
recruiting TIP60. (4) p30 disrupts p300 recruitment to theTRE byTax
thereby reducing viral gene transcription. (5) p30 inhibits tax/rex mRNA
export possibly through REGγ interaction, Rex counteracts p30 inhibitory
function. (6) p30 causes increased phosphorylation in cdc25C on S216 and
reduced phosphorylation on S198 leading to G2/M checkpoint activation.
(7) p30 disrupts Cyclin E-CDK2 complex formation causing delayed S
phase entry. (8) p30 interaction with Regγ down-regulates ATM levels, in
addition p30 inhibits MRN complex formation during DNA damage
activating NHEJ. (B) Schematic representation of p28 functions. p28 is
recruited byTax to the viral promoter where it co-migrates with the
transcriptional machinery until the response element is made. p28
interacts with tax/rex mRNA and inhibits its nuclear export by modulating the
Tap/p15 pathway. p28 interaction with PRMT5 leads to reduced viral gene
expression.
Frontiers in Microbiology | Virology September 2013 | Volume 4 | Article 275 | 6
“fmicb-04-00275” — 2013/9/12 — 18:05 — page 7 — #7
Anupam et al. HTLV-1 p30 vs HTLV-2 p28
p30 and p28 have distinct interactome proﬁles even though they
both interact with some similar proteins; therefore, p30 and
p28 must have divergent functions during the lifecycle of the
viruses.
Comparison of the roles of p30 and p28 has provided fur-
ther insight into HTLV biology. Further studies are needed to
determine their distinct roles in viral latency, low penetrance and
ultimately the differential pathological outcomes of HTLV-1 and
HTLV-2.
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